fulvestrant has been researched along with Bone Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Chasen, BA; Damodaran, S; Fujii, T; Gao, H; Hortobagyi, GN; Ibrahim, NK; Iwase, T; Lim, B; Liu, DD; Lucci, A; Reuben, JM; Saigal, B; Shen, Y; Tahara, RK; Tripathy, D; Ueno, NT | 1 |
| Hu, CT; Long, H; Prijatelj, V; Weng, CF | 1 |
| Cao, J; Gong, C; Hu, X; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Gibson, K; Iyer, S; Milligan, G; Mitra, D; Taylor-Stokes, G; Waller, J | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| Califaretti, N; Chia, SK; Clemons, MJ; Cochrane, B; Dent, RA; Levine, MN; Parpia, S; Pond, GR; Pritchard, KI; Rayson, D; Robidoux, A; Song, X; Warr, D | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Gorska, M; Kuban-Jankowska, A; Wozniak, M; Wyszkowska, RM | 1 |
| Blesa, JM; Candel, VA | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N | 1 |
| Kennedy, AM; Maran, A; Rickard, DJ; Sibonga, JD; Spelsberg, TC; Turner, RT; Zhang, M | 1 |
3 trial(s) available for fulvestrant and Bone Neoplasms
| Article | Year |
|---|---|
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Topics: Adult; Aged; Alpha Particles; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy; Denosumab; Female; Fulvestrant; Humans; Injections, Intravenous; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radioisotopes; Radium; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Piperidines; Postmenopause; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
8 other study(ies) available for fulvestrant and Bone Neoplasms
| Article | Year |
|---|---|
Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antrodia; Bone Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; China; Disease Progression; Duration of Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Time Factors | 2020 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Piperazines; Practice Patterns, Physicians'; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol.
Topics: 2-Methoxyestradiol; Antineoplastic Agents, Hormonal; Apoptosis; Bone Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasm Metastasis; Neoplasm Proteins; Osteosarcoma; Phosphorylation; Protein Processing, Post-Translational | 2016 |
PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient.
Topics: Acetates; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Compassionate Use Trials; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drugs, Investigational; Estradiol; Fulvestrant; Humans; Injections, Intramuscular; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Retreatment | 2010 |
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 2006 |
2-methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Bone Matrix; Bone Neoplasms; Cell Survival; Cytokines; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Interferons; Osteoblasts; Osteosarcoma; Rats; Tumor Cells, Cultured | 2002 |